Global Tuberculosis Vaccine Treatment Market Growth 2023-2029

Global Tuberculosis Vaccine Treatment Market Growth 2023-2029

Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.

Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.
LPI (LP Information)' newest research report, the “Tuberculosis Vaccine Treatment Industry Forecast” looks at past sales and reviews total world Tuberculosis Vaccine Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Tuberculosis Vaccine Treatment sales for 2023 through 2029. With Tuberculosis Vaccine Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tuberculosis Vaccine Treatment industry.
This Insight Report provides a comprehensive analysis of the global Tuberculosis Vaccine Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tuberculosis Vaccine Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Tuberculosis Vaccine Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tuberculosis Vaccine Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tuberculosis Vaccine Treatment.
The global Tuberculosis Vaccine Treatment market size is projected to grow from US$ 72 million in 2022 to US$ 89 million in 2029; it is expected to grow at a CAGR of 89 from 2023 to 2029.
In the last several years, global market of Tuberculosis Vaccine Treatment developed smoothly, with an average growth rate of 0.73%.
The classification of Tuberculosis Vaccine Treatment includes Immune Vaccine and Therapy Vaccine, and the proportion of Immune Vaccine in 2019 is about 99.66%.
Tuberculosis Vaccine Treatment is widely sold through Self-Procurement, UNICEF and Other. The most proportion of Tuberculosis Vaccine Treatment is sold through Self-Procurement, and the proportion in 2019 is 62.14%.
Asia-Pacific is the largest consumption place, with a consumption market share nearly 45% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of 35.66%.
Market competition is intense. Merck, Japan BCG Lab, Serum Institute of India are the leaders of the industry, they occupy the 60% of the market.
This report presents a comprehensive overview, market shares, and growth opportunities of Tuberculosis Vaccine Treatment market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Immune Vaccine
Therapy Vaccine
Segmentation by application
Self-Procurement
UNICEF
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC
Queen Saovabha Mem. Inst
Microgen

Key Questions Addressed in this Report
What is the 10-year outlook for the global Tuberculosis Vaccine Treatment market?
What factors are driving Tuberculosis Vaccine Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Tuberculosis Vaccine Treatment market opportunities vary by end market size?
How does Tuberculosis Vaccine Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.